Aardvark Therapeutics (AARD) News Today $14.85 +0.22 (+1.50%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AARD Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives $31.43 Average Price Target from AnalystsOctober 13 at 3:29 AM | americanbankingnews.comAardvark Therapeutics Aligns with FDA on Trial AmendmentOctober 9, 2025 | tipranks.comAardvark Therapeutics (NASDAQ:AARD) Receives "Sell (E+)" Rating from Weiss RatingsOctober 8, 2025 | marketbeat.comAardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi SyndromeOctober 8, 2025 | globenewswire.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by AnalystsOctober 8, 2025 | marketbeat.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Short Interest UpdateOctober 5, 2025 | marketbeat.comJones Trading Initiates Coverage of Aardvark Therapeutics (AARD) with Buy RecommendationOctober 1, 2025 | msn.comAardvark Therapeutics initiated with a Buy at JonesResearchOctober 1, 2025 | msn.comAardvark Therapeutics (NASDAQ:AARD) Coverage Initiated at Jones TradingOctober 1, 2025 | marketbeat.comPromising Clinical Developments and Strategic Positioning Drive Buy Rating for Aardvark TherapeuticsOctober 1, 2025 | tipranks.comStifel Initiates Coverage of Aardvark Therapeutics (AARD) with Buy RecommendationSeptember 30, 2025 | msn.comGoldman Sachs Group Inc. Purchases New Shares in Aardvark Therapeutics, Inc. $AARDSeptember 30, 2025 | marketbeat.comAardvark Therapeutics initiated with a Buy at StifelSeptember 29, 2025 | msn.comBuy Rating for Aardvark Therapeutics: ARD-101’s Potential in Prader-Willi Syndrome TreatmentSeptember 29, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Gain Therapeutics (GANX) and Novan (NOVN)September 26, 2025 | theglobeandmail.comAardvark Therapeutics, Inc. to Present at Stifel 2025 Virtual Cardiometabolic Forum on September 30September 23, 2025 | quiverquant.comQAardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic ForumSeptember 23, 2025 | globenewswire.comHC Wainwright Reaffirms Buy Rating for Aardvark Therapeutics (NASDAQ:AARD)September 23, 2025 | marketbeat.comAardvark Therapeutics: Undervalued Opportunity in Obesity Treatment Market with Promising Pipeline and Upcoming CatalystsSeptember 23, 2025 | tipranks.comMapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drugSeptember 22, 2025 | finance.yahoo.comInsider Stock Buying Reaches US$730.4k On Aardvark TherapeuticsSeptember 22, 2025 | finance.yahoo.comAardvark Therapeutics (NASDAQ:AARD) CEO Buys $96,600.00 in StockSeptember 17, 2025 | marketbeat.comTien-Li Lee Acquires 10,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) StockSeptember 17, 2025 | insidertrades.comAardvark Therapeutics CEO Makes Bold Stock PurchaseSeptember 16, 2025 | tipranks.comFriday’s Insider Moves: Top Buys and Sells in US StocksSeptember 15, 2025 | investing.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Recommendation of "Buy" by AnalystsSeptember 15, 2025 | marketbeat.comTien-Li Lee Acquires 5,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) StockSeptember 13, 2025 | insidertrades.comAardvark Therapeutics (NASDAQ:AARD) CFO Acquires 6,000 SharesSeptember 12, 2025 | marketbeat.comLB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debutSeptember 12, 2025 | finance.yahoo.comLB Pharma valued at $382 million as shares jump in New York debutSeptember 12, 2025 | msn.comSchizophrenia drug developer LB Pharma jumps in trading debutSeptember 12, 2025 | msn.comAardvark Therapeutics (NASDAQ:AARD) CFO Purchases $48,420.00 in StockSeptember 11, 2025 | insidertrades.comLB Pharmaceuticals raises $285 million in US IPOSeptember 11, 2025 | msn.comAdage Capital Partners GP L.L.C. Makes New $1.88 Million Investment in Aardvark Therapeutics, Inc. $AARDSeptember 10, 2025 | marketbeat.comNeuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPOSeptember 10, 2025 | msn.comLB Pharmaceuticals eyes $322 million valuation in biotech IPO amid sector droughtSeptember 9, 2025 | msn.comCormorant Asset Management LP Acquires New Holdings in Aardvark Therapeutics, Inc. $AARDSeptember 6, 2025 | marketbeat.comAardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 4, 2025 | globenewswire.comAardvark Therapeutics, Inc. (AARD) Presents At Cantor Fitzgerald Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.com500,000 Shares in Aardvark Therapeutics, Inc. $AARD Bought by Braidwell LPSeptember 3, 2025 | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Price Target Cut to $25.00 by Analysts at Bank of AmericaAugust 30, 2025 | marketbeat.comAardvark Therapeutics to Present at Upcoming Investor Conferences in SeptemberAugust 27, 2025 | globenewswire.comAardvark Therapeutics Advances Clinical Trials and FinancialsAugust 26, 2025 | tipranks.comHC Wainwright Has Pessimistic Outlook of AARD Q3 EarningsAugust 22, 2025 | marketbeat.comAardvark Therapeutics, Inc. (NASDAQ:AARD) Given Consensus Rating of "Buy" by BrokeragesAugust 21, 2025 | marketbeat.comCantor Fitzgerald Has Negative View of AARD FY2025 EarningsAugust 19, 2025 | marketbeat.comAardvark Therapeutics (NASDAQ:AARD) Announces Quarterly Earnings ResultsAugust 16, 2025 | marketbeat.comRoyal Bank Of Canada Lowers Aardvark Therapeutics (NASDAQ:AARD) Price Target to $19.00August 16, 2025 | marketbeat.comAardvark Therapeutics price target lowered to $19 from $20 at RBC CapitalAugust 14, 2025 | msn.comAardvark Therapeutics reports Q2 EPS (66c), consensus (60c)August 13, 2025 | msn.com Get Aardvark Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AARD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Media Mentions By Week AARD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AARD News Sentiment▼0.610.75▲Average Medical News Sentiment AARD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AARD Articles This Week▼73▲AARD Articles Average Week Get the Latest News and Ratings for AARD and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aardvark Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SDGR News HROW News SNDX News EVO News AVDL News ZYME News TSHA News ORIC News SION News XERS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AARD) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy this stock before Tesla’s November 6 announcementThe End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | SponsoredThe 7 Warning Signals Flashing Red Right NowA free report revealing the 7 key indicators that have predicted every major economic collapse since 1929. ...American Alternative | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
